Literature DB >> 21978771

Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy.

Anna Tylki-Szymańska1, Johanna E M Groener, Marek Leszek Kamiński, Agnieszka Ługowska, Elżbieta Jurkiewicz, Barbara Czartoryska.   

Abstract

Gaucher disease occurs mainly as a result of a deficiency of the lysosomal enzyme beta-glucocerebrosidase activity. A rare variant form of Gaucher disease is known in which saposin C required for glucosylceramide degradation is deficient. In an earlier paper we described the first cases of two siblings with the non-neuronopathic form of Gaucher disease caused by saposin C deficiency [Tylki-Szymańska et al., 2007]. In this article, we present a follow up of clinical and biochemical findings in one patient who has been treated with miglustat for two years. We observed that administration of miglustat failed to exert any favorable effect on the clinical condition, haematological parameters and glucosylceramide level in the serum. In two individuals (described in this article) very slow deterioration of the peripheral and central nervous systems was observed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978771     DOI: 10.1016/j.ymgme.2011.09.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

2.  Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Ellen Sidransky; Jennifer C Lee
Journal:  Biochemistry       Date:  2013-10-01       Impact factor: 3.162

Review 3.  The role of saposin C in Gaucher disease.

Authors:  Rafael J Tamargo; Arash Velayati; Ehud Goldin; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2012-05-05       Impact factor: 4.797

4.  Sequencing of the GBA coactivator, Saposin C, in Parkinson disease.

Authors:  Bouchra Ouled Amar Bencheikh; Etienne Leveille; Jennifer A Ruskey; Dan Spiegelman; Christopher Liong; Edward A Fon; Guy A Rouleau; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Ziv Gan-Or
Journal:  Neurobiol Aging       Date:  2018-07-02       Impact factor: 4.673

5.  Tissue-specific effects of saposin A and saposin B on glycosphingolipid degradation in mutant mice.

Authors:  Ying Sun; Matt Zamzow; Huimin Ran; Wujuan Zhang; Brian Quinn; Sonya Barnes; David P Witte; Kenneth D R Setchell; Michael T Williams; Charles V Vorhees; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

Review 6.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

Review 7.  Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism.

Authors:  Nahid Tayebi; Grisel Lopez; Jenny Do; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2020-09-15       Impact factor: 11.951

Review 8.  Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.

Authors:  Emily C Daykin; Emory Ryan; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2021-01-09       Impact factor: 4.797

Review 9.  Glucocerebrosidase: Functions in and Beyond the Lysosome.

Authors:  Daphne E C Boer; Jeroen van Smeden; Joke A Bouwstra; Johannes M F G Aerts
Journal:  J Clin Med       Date:  2020-03-09       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.